Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 17.9% during trading on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. Approximately 509,888 shares traded hands during mid-day trading, a decline of 18% from the average daily volume of 624,528 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The stock has a market cap of C$27.01 million, a price-to-earnings ratio of -15.50 and a beta of 0.20. The business’s 50 day moving average is C$0.10 and its 200 day moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- How Investors Can Find the Best Cheap Dividend Stocks
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
